About APAP
Asian Patient
Access Program
ACA Pharma helps innovative medicines and devices reach cash-pay patients faster across Asia—through Macau and Hong Kong fast-track pathways, pilot zones in Mainland China, and compliant patient access programs in other key markets.
Learn More
APAP is designed to expand access to advanced medicines across Asia.
- Provides immediate access to advanced medications for self-paying patients across Asia.
- Eliminates the need for local registration, simplifying the approval process.
- Helps address the unmet needs of 173 million rare disease patients across 48 Asian countries.
- Delivers a streamlined, end-to-end pathway to treatment access.
Asian Patient Access Program
ACA Pharma leverages its New York wholesale platform to help innovative medicines and devices reach patients across Asia without local registration, typically through one-time import permits granted per product and treatment site.
NY-Based · Named Patient AccessAsian Local Patient Access Program
After fast-track registration in key hubs such as Macau and Singapore, innovative medicines and devices can reach local cash-pay patients quickly, while also serving patients who travel from across the region.
Local Access · Cash-PayMacau Fast-Track Registration Program
Macau fast-track registration can open broader access in Mainland China pilot zones such as Hainan and the Greater Bay Area, expanding cash-pay access and helping support accelerated national approval.
Macau · China BridgeBridging Access Across Asia
Self-paying patients in Asia can access innovative treatments through ACA Pharma’s U.S. supply channels, without waiting for full local registration.
New York–Based Asian Patient Access Program
Help self-paying patients in Asia access innovative treatments through ACA Pharma’s U.S. wholesale channels, without waiting for local registration.
- Originators authorize products into ACA Pharma’s U.S. wholesale channels (e.g., ICS, ASD Healthcare, AmerisourceBergen).
- Treatments are delivered under temporary import permits issued for hospitals or individual patients.
- Supported by ACA Pharma’s 30+ years of experience and specialty provider network across Asia.
- Reduces regulatory friction and speeds access to advanced and life-saving therapies.
Asian Local Patient Access Program (Macau & Singapore)
Build local patient access programs after fast-track registration in Macau and Singapore, expanding access for self-paying patients across Asia.
- Fast-track registration pathways are exempt from local clinical trial requirements.
- Programs support self-paying patients using U.S. or European market reference pricing.
- Creates efficient access channels while addressing local policy and market sensitivities.
From Registration to Patient Access
ACA Pharma helps translate fast-track approvals in Macau and Singapore into practical treatment pathways for self-paying patients across Asia.
A Faster Path to Market Access
A streamlined registration route that helps bring innovative therapies to patients faster and supports broader expansion into Greater China.
Macau Fast-Track Registration Program
Rapidly access major markets like the Greater Bay Area, Hainan, Beijing and Shanghai with a streamlined 30-90 day registration process.
- Enables faster registration without local clinical trials in Macau.
- Supports early patient access and real-world evidence generation for broader market expansion.
- Creates a foundation for follow-on access in the Greater Bay Area, Hainan, and other pilot zones.
- RWE generated supports accelerated national approval for clinically urgent and rare disease therapies.
Why Partner with ACA Pharma
ACA Pharma offers originators a practical dual-path strategy: immediate patient access today, with a clear foundation for broader market growth tomorrow. Through APAP, we help innovative therapies reach self-paying patients across Asia quickly and compliantly, while preserving flexibility for long-term expansion.
Deep Regional Expertise
- 30+ years of experience in Asia’s pharmaceutical markets
- Established network across leading hospitals and specialists
- Local execution capabilities across key Asian jurisdictions
- Experienced in navigating complex access pathways
Fast Patient Access
- APAP enables rapid access for self-paying patients in Asia
- Avoids the delays of full local registration
- Simplifies market entry for originators
- Helps patients access advanced therapies sooner
Built for Long-Term Growth
- Supports follow-on expansion beyond initial access
- Flexible models aligned with originator strategy
- Creates a bridge toward broader commercialization
- Adapts to local market and policy realities
Asia Market Entry Specialists
On-the-ground execution, broader reach
We support rare-disease programs across therapeutic areas, from early access to multi-country expansion beyond China
